EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of intravitreal Ziv-Aflibercept for the treatment of macular edema: A systematic review and meta-analysis

F Munayco-Guillén, M García-Roa, M Vázquez-Membrillo, R Pichardo-Rodríguez

Archivos de la Sociedad Española de Oftalmología (English Edition) · 2026-06 · 101 (6) · 502465

DOI: 10.1016/j.oftale.2026.502465 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Archivos de la Sociedad Española de Oftalmología (English Edition), 2026-06. Verfasst von F Munayco-Guillén und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Cirugía de Retina y Vítreo, Instituto Nacional de Oftalmología (INO), Lima, Peru; Retina Peru Research Group (REPEREG), Lima, Peru; G…. Hauptthemen laut MEDLINE: Macular Edema, Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Angiogenesis Inhibitors. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE Intravitreal Ziv-Aflibercept (ZA-IV) is a recombinant fusion protein used to treat macular diseases. Several studies have demonstrated its efficacy and safety. The objective was to evaluate the efficacy and safety of ZA-IV in the treatment of diabetic macular edema (DME) and macular edema secondary to retinal vein occlusion (RVO). MATERIALS AND METHODS Systematic review with meta-analysis (PROSPERO: CRD42024542788), with searches in PubMed, EMBASE, and Web of Science up to April 2024. Observational studies and randomized controlled trials (RCTs) were included. Efficacy was determined by best-corrected visual acuity (BCVA) and central macular thickness (CMT). Safety was assessed based on the reports in the studies. Risk of bias was assessed using the Robins-I and Cochrane RoB 2.0 tools. RESULTS Of 503 studies, 8 observational studies and 5 RCTs were included. In DME, RCTs showed a reduction in CMT (-105 μm; 95% CI: -129.8 to -80.3; I2: 0%) and in BCVA a LogMAR reduction (-0.29; 95% CI: -0.36 to -0.21; I2: 0%). Observational studies in DME showed a reduction in CMT (-108 μm; 95% CI: -133 to -83.1; I2: 34%) and in BCVA a LogMAR reduction (-0.2; 95% CI: -0.26 a -0.14; I2: 0%). In RVO, RCTs showed a reduction in CMT (-230 μm; 95% CI: -367 to -94; I2: 46%). Observational studies in EMSOV showed a reduction in GMC (-160 μm; 95% CI: -257 to -64; I2: 74%) and in BCVA (best corrected visual acuity) a reduction in LogMAR (-0.2; 95% CI: -0.26 to -0.14; I2: 50%). No serious ocular or systemic adverse effects were reported. CONCLUSION ZA-IV demonstrated efficacy and is potentially safe for the treatment of EMD and EMSOV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorAngiogenesis InhibitorsHumansIntravitreal InjectionsRetinal Vein OcclusionTreatment OutcomeDiabetic RetinopathyVisual AcuityRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Diabetes mellitusEdema macularEfficacyEficaciaIntravitreal injectionsInyecciones intravítreasMacular edemaOclusión de la vena retinianaRetinal vein occlusionSafetySeguridad

Substanzen

Recombinant Fusion ProteinsafliberceptReceptors, Vascular Endothelial Growth FactorAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Departamento de Cirugía de Retina y Vítreo, Instituto Nacional de Oftalmología (INO), Lima, Peru; Retina Peru Research Group (REPEREG), Lima, Peru; Grupo Peruano de Evidencia Clínica y Real-World Evidence (GPECRWE), Lim…
  • Departamento de Cirugía de Retina y Vítreo, Instituto Mexicano de Oftalmología (IMO), Querétaro, Querétaro, Mexico.
  • Retina Peru Research Group (REPEREG), Lima, Peru; Grupo Peruano de Evidencia Clínica y Real-World Evidence (GPECRWE), Lima, Peru.

Zitieren

APA

Munayco-Guillén, F., García-Roa, M., Vázquez-Membrillo, M., & Pichardo-Rodríguez, R. (2026). Efficacy and safety of intravitreal Ziv-Aflibercept for the treatment of macular edema: A systematic review and meta-analysis. Archivos de la Sociedad Española de Oftalmología (English Edition), 101(6), 502465. https://doi.org/10.1016/j.oftale.2026.502465

Vancouver

Munayco-Guillén F, García-Roa M, Vázquez-Membrillo M, Pichardo-Rodríguez R. Efficacy and safety of intravitreal Ziv-Aflibercept for the treatment of macular edema: A systematic review and meta-analysis. Archivos de la Sociedad Española de Oftalmología (English Edition). 2026;101(6):502465. doi:10.1016/j.oftale.2026.502465

BibTeX
@article{MunaycoGuilln2026,
  author = {Munayco-Guillén, F and García-Roa, M and Vázquez-Membrillo, M and Pichardo-Rodríguez, R},
  title = {Efficacy and safety of intravitreal Ziv-Aflibercept for the treatment of macular edema: A systematic review and meta-analysis},
  journal = {Archivos de la Sociedad Española de Oftalmología (English Edition)},
  year = {2026},
  volume = {101},
  number = {6},
  pages = {502465},
  doi = {10.1016/j.oftale.2026.502465}
}
Kostenlos starten →